Article
Schistosomiasis Drug Discovery in the Era of Automation and Artificial Intelligence
Registro en:
MOREIRA FILHO, José T. et al. Schistosomiasis Drug Discovery in the Era of Automation and Artificial Intelligence. Front. Immunol., v. 12, Article 642383, 29 p, May 2021.
1664-3224
10.3389/fimmu.2021.642383
Autor
Moreira Filho, José T.
Silva, Arthur C.
Dantas, Rafael F.
Gomes, Barbara F.
Souza Neto, Lauro R.
Brandão Neto, Jose
Owens, Raymond J.
Furnham, Nicholas
Neves, Bruno J.
Silva Junior, Floriano P.
Andrade, Carolina H.
Resumen
Schistosomiasis is a parasitic disease caused by trematode worms of the genus
Schistosoma and affects over 200 million people worldwide. The control and treatment
of this neglected tropical disease is based on a single drug, praziquantel, which raises
concerns about the development of drug resistance. This, and the lack of efficacy of
praziquantel against juvenile worms, highlights the urgency for new antischistosomal
therapies. In this review we focus on innovative approaches to the identification of
antischistosomal drug candidates, including the use of automated assays, fragment based screening, computer-aided and artificial intelligence-based computational
methods. We highlight the current developments that may contribute to optimizing
research outputs and lead to more effective drugs for this highly prevalent disease, in a
more cost-effective drug discovery endeavor.